Indian COVID-19 diagnostics market is estimated to see a decline in CAGR of 19.9% during the forecast period. India has significant scope for COVID-19 diagnostic owing to robust increase in the diagnostic tests in the country coupled with the growing number of positive COVID-19 cases. The Indian government expanded the network of government laboratories designated to test samples of suspected COVID-19 cases to 920 laboratories. Among 920 government laboratories, 421 were approved to test for Real-Time PCR (RT PCR) tests, 467 for TrueNat screening tests, and 32 for CBNAAT testing. Moreover, 446 private laboratories were approved to conduct COVID-19 tests. Among 446 private laboratories, 275 are approved to test RT PCR tests, 94 to test for TrueNat tests and 77 to test for CBNAAT testing in the country.

The RT-PCR throat/nasal swab test has been the key diagnostic tests that were conducted across the country. The rapid antibody tests were withdrawn by ICMR within a few weeks due to over reliability concerns. However, ICMR has recently encouraged states to conduct serosurveys using an IgG ELISA test for COVID-19 diagnosis. RT-PCR test diagnoses the infection by detecting the presence of live virus, the antibody test provides information about the history of infection by detecting antibodies specific to COVID-19. In the early stages of a pandemic, or after a period of suppression, RT-PCR is useful to identify the infected persons, trace their contacts, and isolate them to limit the spread of infection.

Indian COVID-19 diagnostics market is segmented on the basis of technology type, end-use, sample type, and product type. By end-use, the COVID-19 diagnostic market is divided into laboratories, hospitals, diagnostic centers & clinics, and research institutes. By product type, the market is further segmented into instruments, reagents & kits, and laboratory testing services. By Sample type, the market is divided into oropharyngeal & nasopharyngeal swabs, blood, urine, saliva, and others. By technology type, the market is further segmented into PCR Test, Antigen Test, Serology Test, and Rapid/ PoC Test. Among these, the PCR segment has a major share in the COVID-19 diagnostics market. The factor that enhances the PCR test adoption includes a wide availability of tests and generation of the accurate results. However, due to its time consuming and expensive nature, these tests are substituted with other tests such as serology tests.

The companies which are contributing to the growth of the Indian COVID-19 diagnostics market include Biogenix Inc. Pvt. Ltd., BioGenomics Ltd., J Mitra & Co. Pvt Ltd., Mylab Discovery Solutions Pvt Ltd., and Aspen Laboratories Pvt. Ltd. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in June 2020, J Mitra & Co. Pvt Ltd., a member of National Biomedical Resources Indigenization Consortium (NBRIC), developed and launched an indigenous total antibody test kit for COVID-19 based on (IgM, IgG, IgA). The kit is the MICROLISA test for Indian markets. Based on the Double-Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA.

Research Methodology

The market study of the Indian COVID-19 diagnostics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

1. Indian COVID-19 Diagnostics Market Research and Analysis by Type
2. Indian COVID-19 Diagnostics Market Research and Analysis by Technology Type
3. Indian COVID-19 Diagnostics Market Research and Analysis by Sample Type
4. Indian COVID-19 Diagnostics Market Research and Analysis by End-User

The Report Covers

• Comprehensive research methodology of the Indian COVID-19 diagnostics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Indian COVID-19 diagnostics market.
• Insights about market determinants which are stimulating the Indian COVID-19 diagnostics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.